Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria

The PNH review considered the medicine eculizumab. The Expert Panel considered this review at its October 2020 meeting. These resources provide a summary of the review and recommendations.

Collection description

This collection contains guidelines, forms and documents related to accessing eculizumab (Soliris®) under the Life Saving Drugs Program. Click to view the Soliris® product information on the Therapeutic Goods Administration website.

Medicines review documents

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Health sector

Help us improve

If you would like a response please use the enquiries form instead.